Name (Synonyms) | Correlation | |
---|---|---|
drug74 | ACT-541478 300 mg Wiki | 1.00 |
drug76 | ACT-541478 high or low dose (or placebo) Wiki | 1.00 |
drug73 | ACT-541478 30 mg Wiki | 1.00 |
drug72 | ACT-541478 1000 mg Wiki | 1.00 |
drug70 | ACT-541478 10 mg Wiki | 1.00 |
drug75 | ACT-541478 dose E1 Wiki | 1.00 |
drug71 | ACT-541478 100 mg Wiki | 1.00 |
drug1690 | Matching placebo Wiki | 0.58 |
There is one clinical trial.
Severe Acute respiratory syndrome coronovirus (SARS-CoV-2) was first described in Wuhan in December 2019. It quickly spread to rest of the world and was declared pandemic by World health organisation. Initial case series focused on lung involvement in the form alveolar haemorrhages and respiratory failure. However, subsequently, there have been reports of kidney involvement resulting in severe acute kidney injury. However, the reported incidence from Chinese data has been less than 5% and detailed epidemiology of AKI in COVID-19 disease is lacking.
Description: This is the proportion of patients with Acute kidney injury in COVID-19
Measure: Incidence of Acute kidney injury in COVID-19 Time: 7 daysDescription: This is the number of deaths in COVID-19 AKI patients
Measure: All-cause mortality in AKI patients Time: 7 days